Division of Gynecologic Oncology, The University of Alabama at Birmingham, 1700 6th Ave South, 10th Floor Suite 10100, Birmingham, AL 35233, USA.
Expert Opin Biol Ther. 2011 Jun;11(6):751-62. doi: 10.1517/14712598.2011.566854. Epub 2011 Mar 11.
Immunotherapy, in its entirety, represents a promising field at the forefront of cancer. Treatment with potent cytokine IL-12 has provided science with many challenges, but has also demonstrated promise as therapeutic strategy in ovarian cancer.
This review examines the anti-tumor mechanism of action of IL-12 and the development of IL-12 as a potential therapeutic option in a variety of malignancies. It also reviews the immunogenicity of ovarian cancer and covers preclinical and clinical trials that have contributed to the advancement of IL-12 as a potential therapy for ovarian malignancy. The obstacles that researchers have overcome and currently face regarding the use of IL-12 in clinical ovarian cancer trials are also discussed.
IL-12, as a therapeutic modality, is mechanistically logical and shows great promise in preclinical trials. Further clinical studies are warranted to optimize the potential of IL-12 as a treatment strategy for ovarian cancer.
免疫疗法作为癌症治疗领域的一个新兴分支，具有广阔的发展前景。细胞因子 IL-12 的治疗应用为癌症治疗带来了新的机遇和挑战。
本文回顾了 IL-12 的抗肿瘤作用机制，及其在多种恶性肿瘤治疗中的应用潜力。本文还探讨了卵巢癌的免疫原性，并综述了有助于推动 IL-12 成为卵巢恶性肿瘤潜在治疗方法的临床前和临床试验。此外，本文还讨论了研究人员在将 IL-12 应用于临床卵巢癌试验中克服和面临的障碍。
作为一种治疗方式，IL-12 在机制上具有合理性，并在临床前试验中显示出巨大的应用潜力。需要进一步的临床研究来优化 IL-12 作为卵巢癌治疗策略的潜力。
